5. Subjects must have at least one tumor lesion with a longest diameter of ≥0.5 cm that can be easily palpated or detected by ultrasound to facilitate intratumoral injection of CMP-001 (i.e., tumor in skin, muscle, subcutaneous tissue or accessible lymph node).